Rituximab in Patients With ST-elevation Myocardial Infarction
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The main objective is to compare the effect of a single injection of two doses of rituximab
versus placebo on 6 months left ventricular systolic function, using CMR, in patients who
have had an acute anterior STEMI.
The primary endpoint is the left ventricular ejection fraction (LVEF) by CMR at 6 months.
Phase:
Phase 2
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France